Heather Stefanski, MD, PhD

The ACCESS study of post-transplant cyclophosphamide in stem cell transplant showed that even 6/8 and 5/8 HLA matches can be considered as donors.

Longer follow-up of patients receiving a modern prophylactic regimen shows positive outcomes for preventing chronic GVHD and relapse after stem cell transplant.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

The ACCESS study reveals that posttransplant cyclophosphamide improves survival rates for patients with mismatched unrelated donor transplants, expanding donor options.

Heather Stefanski, MD, PhD, discusses the unmet needs for patients undergoing bone marrow and stem cell transplants.